Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 1
1974 1
1975 4
1976 3
1977 7
1978 4
1979 5
1981 2
1982 4
1983 2
1984 2
1985 5
1986 2
1987 5
1988 1
1989 3
1990 6
1991 6
1992 5
1993 2
1994 5
1995 3
1996 5
1998 5
1999 2
2000 4
2001 3
2002 2
2003 3
2004 5
2005 3
2006 5
2007 2
2008 6
2009 3
2010 9
2011 6
2012 9
2013 12
2014 17
2015 7
2016 6
2017 9
2018 5
2019 6
2020 11
2021 9
2022 8
2023 6
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

233 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Abnormal glucagon level"
Page 1
Metformin--mode of action and clinical implications for diabetes and cancer.
Pernicova I, Korbonits M. Pernicova I, et al. Nat Rev Endocrinol. 2014 Mar;10(3):143-56. doi: 10.1038/nrendo.2013.256. Epub 2014 Jan 7. Nat Rev Endocrinol. 2014. PMID: 24393785 Review.
Metformin exerts its prevailing, glucose-lowering effect by inhibiting hepatic gluconeogenesis and opposing the action of glucagon. The inhibition of mitochondrial complex I results in defective cAMP and protein kinase A signalling in response to glucagon. ...Metfor …
Metformin exerts its prevailing, glucose-lowering effect by inhibiting hepatic gluconeogenesis and opposing the action of glucagon. T …
Serum Uric Acid and Diabetes: From Pathophysiology to Cardiovascular Disease.
Katsiki N, Dimitriadis GD, Mikhailidis DP. Katsiki N, et al. Curr Pharm Des. 2021;27(16):1941-1951. doi: 10.2174/1381612827666210104124320. Curr Pharm Des. 2021. PMID: 33397230 Review.
However, it has also been associated with the development of type 2 diabetes mellitus (T2DM) and cardiometabolic and cardiovascular diseases. Pathophysiologically, elevated serum uric acid (SUA) levels may be associated with abnormal lipid and glucose metabolism. .. …
However, it has also been associated with the development of type 2 diabetes mellitus (T2DM) and cardiometabolic and cardiovascular diseases …
Diabetes and branched-chain amino acids: What is the link?
Bloomgarden Z. Bloomgarden Z. J Diabetes. 2018 May;10(5):350-352. doi: 10.1111/1753-0407.12645. Epub 2018 Feb 13. J Diabetes. 2018. PMID: 29369529
The BCAA stimulate secretion of both insulin and glucagon and, when given orally, of both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), with oral administration leading to greater and more prolonged insulin and glucagon …
The BCAA stimulate secretion of both insulin and glucagon and, when given orally, of both glucagon-like peptide-1 (GLP-1) and …
GLP-1 receptor agonists, polycystic ovary syndrome and reproductive dysfunction: Current research and future horizons.
Papaetis GS, Kyriacou A. Papaetis GS, et al. Adv Clin Exp Med. 2022 Nov;31(11):1265-1274. doi: 10.17219/acem/151695. Adv Clin Exp Med. 2022. PMID: 35951627 Free article. Review.
The principal goal of all therapeutic approaches to individuals with reproductive abnormalities is the treatment of subfertility or the regulation of menstruation when pregnancy is not desired. ...The GLP-1R agonists have achieved remarkable weight reduction and abdominal …
The principal goal of all therapeutic approaches to individuals with reproductive abnormalities is the treatment of subfertility or t …
The Role of Glp-1 Receptor Agonists in Insulin Resistance with Concomitant Obesity Treatment in Polycystic Ovary Syndrome.
Bednarz K, Kowalczyk K, Cwynar M, Czapla D, Czarkowski W, Kmita D, Nowak A, Madej P. Bednarz K, et al. Int J Mol Sci. 2022 Apr 14;23(8):4334. doi: 10.3390/ijms23084334. Int J Mol Sci. 2022. PMID: 35457152 Free PMC article. Review.
Although it is not included in the diagnostic criteria of PCOS, there is a crucial role of this metabolic impairment, which along with hormonal abnormalities, increase each other in a vicious circle of PCOS pathogenesis. ...They also tend to improve fertility either by inc …
Although it is not included in the diagnostic criteria of PCOS, there is a crucial role of this metabolic impairment, which along with hormo …
Glucagon and diabetes.
Raskin P, Unger RH. Raskin P, et al. Med Clin North Am. 1978 Jul;62(4):713-22. doi: 10.1016/s0025-7125(16)31767-9. Med Clin North Am. 1978. PMID: 355737 Review.
We have considered the evidence, first, that the presence of glucagon is essential in the pathogenesis of the full syndrome that results from complete insulin deficiency; second, that in the diabetic in whom insulin levels are relatively fixed, a rise in glucagon …
We have considered the evidence, first, that the presence of glucagon is essential in the pathogenesis of the full syndrome that resu …
Improvement of glycaemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 1 study).
Takahashi Y, Nomoto H, Yokoyama H, Takano Y, Nagai S, Tsuzuki A, Cho KY, Miya A, Kameda H, Takeuchi J, Taneda S, Kurihara Y, Atsumi T, Nakamura A, Miyoshi H; SWITCH-SEMA 1 study group. Takahashi Y, et al. Diabetes Obes Metab. 2023 Jun;25(6):1503-1511. doi: 10.1111/dom.14998. Epub 2023 Feb 28. Diabetes Obes Metab. 2023. PMID: 36722623 Clinical Trial.
MATERIALS AND METHODS: In this multicentre, open-labelled, prospective, randomized, parallel-group comparison study, patients treated with liraglutide 0.9-1.8 mg/day (plan A) or dulaglutide 0.75 mg/week (plan B) were either switched to semaglutide or continued current ther …
MATERIALS AND METHODS: In this multicentre, open-labelled, prospective, randomized, parallel-group comparison study, patients treated …
Neuroendocrine Determinants of Polycystic Ovary Syndrome.
Szeliga A, Rudnicka E, Maciejewska-Jeske M, Kucharski M, Kostrzak A, Hajbos M, Niwczyk O, Smolarczyk R, Meczekalski B. Szeliga A, et al. Int J Environ Res Public Health. 2022 Mar 6;19(5):3089. doi: 10.3390/ijerph19053089. Int J Environ Res Public Health. 2022. PMID: 35270780 Free PMC article. Review.
A diagnosis of PCOS is established based the presence of two out of three clinical symptoms, which are criteria accepted by the ESHRE/ASRM (European Society of Human Reproduction and Embryology/American Society for Reproductive Medicine). ...Other studies have proved that …
A diagnosis of PCOS is established based the presence of two out of three clinical symptoms, which are criteria accepted by the ESHRE …
PTEN, Insulin Resistance and Cancer.
Li A, Qiu M, Zhou H, Wang T, Guo W. Li A, et al. Curr Pharm Des. 2017;23(25):3667-3676. doi: 10.2174/1381612823666170704124611. Curr Pharm Des. 2017. PMID: 28677502 Review.
Its fundamental principle is inability of insulin to exert its normal metabolic effects, and nutrient imbalance and abnormal lipid accumulation in skeletal muscle, liver and adipose tissues. ...Selective disruption of PTEN in pancreatic alpha-cells demonstrates that a lack …
Its fundamental principle is inability of insulin to exert its normal metabolic effects, and nutrient imbalance and abnormal lipid ac …
Glucagon-like peptide-1 receptor agonists decrease hyperinsulinemia and hyperandrogenemia in dehydroepiandrosterone-induced polycystic ovary syndrome mice and are associated with mitigating inflammation and inducing browning of white adipose tissue.
Zhang Y, Lin Y, Li G, Yuan Y, Wang X, Li N, Xiong C, Yang Y, Ma Y, Zhang Z, Ding X. Zhang Y, et al. Biol Reprod. 2023 Jun 9;108(6):945-959. doi: 10.1093/biolre/ioad032. Biol Reprod. 2023. PMID: 36930063 Free PMC article.
Furthermore, toll-like receptor 4 and phosphorylation of nuclear factor-kappa B protein levels were decreased by glucagon-like peptide-1 receptor agonists in ovary. Notably, after glucagon-like peptide-1 receptor agonist intervention, the expression of brown …
Furthermore, toll-like receptor 4 and phosphorylation of nuclear factor-kappa B protein levels were decreased by glucagon-like …
233 results